CD8A as a Prognostic and Immunotherapy Predictive Biomarker Can Be Evaluated by MRI Radiomics Features in Bladder
Zongtai Zheng1, Yadong Guo2,3, Xiongsheng Huang1,4
1Department of Urology, Guangdong Second Provincial General Hospital, Guangzhou 510317, China.
Cancers
|October 14, 2022
Summary
CD8A gene expression is a promising biomarker for predicting bladder cancer prognosis and immunotherapy response. Radiomics signature can preoperatively predict CD8A levels, aiding treatment decisions.
Area of Science:
- Oncology
- Immunology
- Radiology
Background:
- CD8A molecule (CD8A) is a key T cytotoxic pathway gene with potential as a biomarker for immunotherapy response and immune cell infiltration.
- Investigating CD8A's role in bladder cancer (BCa) prognosis and its preoperative prediction via radiogenomics is crucial.
Purpose of the Study:
- To evaluate the clinical predictive value of CD8A in BCa prognosis and tumor microenvironment (TME).
- To develop a radiomics signature for preoperative prediction of CD8A expression in BCa.
Main Methods:
- Analysis of 12 T cytotoxic pathway-related genes in BCa.
- Correlation analysis between CD8A expression and immune cell infiltration (T cells, Macrophages M1).
- Development and validation of a radiomics signature using MRI radiomics and RNA-sequence data from 111 BCa samples.
Main Results:
- CD8A was identified as a protective gene in BCa, highly correlated with T cells and Macrophages M1.
- Low CD8A expression correlated with immunotherapy failure and poor survival in advanced cancer.
- The radiomics signature effectively predicted CD8A expression with high AUC values (0.857 training, 0.844 validation).
Conclusions:
- CD8A is a novel indicator for BCa prognosis and predicting immunotherapy response.
- A radiomics signature shows potential for preoperative prediction of CD8A expression in BCa patients.
